The Complete List and Analysis of the Best Selling Drugs for Diabetes in 2017. All the Top Anti-Diabetic Products in…

The Complete List and Analysis of the Best Selling Drugs for Diabetes in 2017. All the Top Anti-Diabetic Products in…
The Complete List and Analysis of the Best Selling Rheumatology Drugs in 2017. All the Top Rheumatology Products in the…
The Complete List and Analysis of the Best Selling Oncology Drugs in 2017. All the Top Oncology Products in the…
The Complete List and Analysis of the Best Selling Cardiovascular Drugs in 2017. All the Top Cardiovascular Products in the…
The Complete List and Analysis of the Best Selling Drugs in 2017. All the Top Products in the Pharmaceutical and…
All the most promising drugs approved by FDA in 2017 and their future potential In 2017, the Center for Drug…
Global Genome Editing Market The global genome editing market in 2016 is estimated at USD 2.84 Billion and forecasted to…
Major pharmaceutical companies have invested immense resources into developing innovative treatments for cancer. Since 1997 the list of the best selling…
In 2016, global diabetes drugs market was valued at USD 30.95 billions and is estimated to grow by 7.5% to…
Poly (ADP-ribose) polymerase (PARP) inhibitors are targeted therapies that are used for multiple indications, most commonly, cancer. PARP aids in…
What’s a forecast? Forecasting in the pharmaceutical industry may be viewed as a means of predicting the future, a tool…
Rheumatology drug market is a highly consolidated market with the top ten players accounting for nearly 90% of the market…
The global oncology market is expected to grow at a rate of 7.5% with top-ten companies accounting for more than…
The global prescription drug market is expected to grow by 6% from 2016 to 2022 to reach nearly USD 1.05…
In 2016, the Center for Drug Evaluation and Research (CDER) of FDA approved 22 novel drugs. This represents a significant…
The top-ten oncology drugs accounted for 36% of the total oncology drugs market. The list is headed by Avastin, an oncology product manufactured by Roche
With the increasing prevalence of different health conditions requiring expensive lifelong treatment, the global sales of therapeutics have been expected…
The increasing demand for medicines and other biologic products paved the way to the development of methods that can speed up its production in order to meet the needs of its consumers. One of which is the utilization of biosimilar product, which is defined by the U.S. Food and Drug Administration (FDA) as ‘a biological product that is approved based on a showing that it is highly similar to an FDA-approved biological product, known as a reference product, and has no clinically meaningful differences in terms of safety and effectiveness from the reference product’.
The emergence of biosimilars is known to be in accordance with the Patient Protection and Affordable Care Act (Affordable Care Act) signed by US President Barack Obama on March 23, 2010. This law was promulgated in order to establish an expedited licensure pathway for biological products that exhibited no significant difference, in terms of safety and efficacy, with an existing FDA-licensed biological product (U.S. Food and Drug Administration, 2016).
Pharmaceutical companies venturing on the production of biosimilars have envisioned market opportunities and have found some interesting advantages of this undertaking. By the year 2020, biologics with estimated sales of $100 billion will lose its patent protection. Since the development of an original biological product entails a complex process and expensive costs, several companies tend to produce biosimilars, instead. Biosimilars are thought to have greater chances of making it to the market, therefore less risky than branded biologics. Aside from this, investment in biologics is much higher compared to that of biosimilars with relatively lower probability of success. In fact, as of December 2012, it was estimated that the average cost of research and development (R&D) of new drugs may reach $1.9 billion with only 1/10 probability of commercial success after approximately 13.5 years of R&D (Blackstone & Joseph, 2013).
The following will give us an overview of some of the biosimilars which have been available in the market, according to FDA’s Center for Drug Evaluation and Research (U.S. FDA Center for Drug Evaluation and Research , 2016).
Rare diseases are known to bring significant impact on the quality of life of thousands to millions of people across…
The prescription drugs market includes a large number of formulation products that address a diverse array of therapeutic requirements. Prescription…